"The EDSS has a number of limitations and may also measure changes that are not related to MS, such as older age and multiple ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A multiple sclerosis patient shares essential guidance from her 13-year diagnostic journey, offering hope and practical tips ...

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

Many people living with the degenerative neurological disease multiple sclerosis (MS) are premenopausal women. This means ...